Firefly Neuroscience Jumps 34% on NeuroSigma ADHD Deal

Firefly Neuroscience, Inc. (NASDAQ: AIFF) shares rose 34.45% to $1.60 by 16:04 GMT on Sept. 25, 2026, after the company announced a strategic partnership to promote NeuroSigma's Monarch eTNS System — the first FDA-cleared non-drug treatment for pediatric ADHD — across its nationwide network of Evoke EEG/ERP clinician customers.

Firefly Neuroscience, Inc. (NASDAQ: AIFF) shares climbed 34.45% to $1.60 by 16:04 GMT on Friday, Sept. 25, 2026, after the artificial-intelligence neuroscience company said it had struck a strategic partnership with NeuroSigma, Inc., a privately held bioelectronic medical device maker. The stock traded between $1.48 and $1.77 on the session, against a prior close of $1.19 — meaning that at the intraday peak the shares were up roughly 48.7% on the day before giving back part of the move.

The scale of the reaction is the story as much as the deal itself. The three main equity benchmarks were higher but placid: the S&P 500 proxy SPY was up 0.55% at $771.43, the Nasdaq 100 proxy QQQ up 0.55% at $745.16, and the Dow proxy DIA up 0.84% at $516.98. A one-day gain of more than a third against that backdrop is the signature of a micro-cap where a single commercial announcement can reset the entire investment case.

What the two companies actually agreed

Under the partnership, Firefly will introduce NeuroSigma's Monarch eTNS System to the psychiatry, neurology and behavioral health practices that already use Firefly's Evoke platform. Evoke is an FDA 510(k)-cleared, AI-powered system that records EEG and ERP data — electroencephalography measures the brain's electrical activity, while event-related potentials capture the brain's response to a specific stimulus — and turns it into objective readouts a clinician can act on.

The Monarch eTNS System delivers external trigeminal nerve stimulation and is, per the announcement, the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder cleared by the U.S. Food and Drug Administration. The two products sit on opposite sides of the same clinical encounter: one helps characterise what is happening in a child's brain, the other offers a treatment route that does not involve a stimulant prescription.

The news release framed the logic plainly, saying the collaboration "brings together complementary technologies designed to address two significant needs in pediatric ADHD care: access to objective information about brain function and availability of a non-medication treatment option for eligible patients."

Why distribution, not invention, is the valuable part

Neither company is launching a new product here. What changes is reach. Medical device companies of NeuroSigma's size typically face a slow, expensive grind to get a device in front of prescribing clinicians one practice at a time. Firefly's installed base of Evoke customers is a pre-qualified audience: these are clinicians who have already bought into objective neurophysiological measurement and who are already seeing the patient population Monarch is cleared to treat.

For Firefly, the arrangement adds commercial substance to a platform business without requiring it to build or acquire a therapeutic device. Every Evoke placement becomes a channel rather than just a unit sale. That is the argument the market appears to have priced on Friday, as Baystreet reported the shares hiking on the announcement.

What the announcement does not contain is the number investors will eventually need: there is no disclosed revenue share, minimum commitment, upfront payment or target for device placements. Until that detail emerges, the partnership is a distribution agreement of unquantified value, and the share price move reflects expectation rather than booked business.

The size of the pediatric ADHD market behind the deal

The commercial premise rests on prevalence. A 2024 study published in the Journal of Clinical Child & Adolescent Psychology found that approximately one in nine U.S. children has received an ADHD diagnosis. That is an unusually large addressable population for a single cleared indication, and it explains why a non-drug option carries strategic weight beyond its current sales base.

Two forces make the timing plausible. Stimulant medication supply has been a recurring point of friction for families and prescribers, and parental resistance to medicating young children is a durable feature of the market rather than a passing sentiment. A device-based alternative with FDA clearance sidesteps both objections — but it also has to be found, understood and trusted by clinicians before it is used, which is precisely the gap Firefly says it is filling.

Diagnosis itself is the other half. ADHD assessment leans heavily on questionnaires and clinical judgement. A platform that adds measurable brain-function data to that process is easier to sell into a practice if it also opens a treatment pathway, and vice versa. Each product improves the sales case for the other.

What to watch from here

Three things will determine whether Friday's move holds. First, disclosure of commercial terms: any revenue participation, milestone structure or exclusivity would let analysts attach a number to the arrangement instead of a narrative. Second, the pace of Evoke placements — the partnership's value scales directly with how many clinician sites Firefly has and how fast that count grows. Third, evidence of actual Monarch orders flowing through the channel, which would appear in NeuroSigma's business first and in Firefly's reported results only to the extent the agreement gives it economics.

Investors should also weigh the mechanics of the stock itself. At $1.60, Firefly sits in the low-priced small-cap territory where liquidity is thin and single-session moves of this magnitude are common in both directions. The day's range — a $0.29 spread between the $1.48 low and the $1.77 high — is wider than the entire daily move in any of the three benchmark ETFs. That is not a criticism of the business; it is a description of the risk profile attached to owning it.

Finally, note what the announcement is silent on. There is no guidance change, no financing news, and no clinical data attached to the release. Partnerships that expand a channel are cheap to announce and hard to value. The next disclosure that includes either a dollar figure or a placement count will do far more to settle Firefly's valuation than Friday's headline did.

Key facts

• AIFF share price: $1.60, +34.45% as of 16:04 GMT, Sept. 25, 2026
• Day range: $1.48–$1.77, prior close $1.19
• Partner: NeuroSigma, Inc., maker of the Monarch eTNS System
• Market context: S&P 500 proxy SPY +0.55% at $771.43 the same session

Frequently asked questions

What did Firefly Neuroscience announce?

Firefly Neuroscience announced a strategic partnership with NeuroSigma, Inc., a bioelectronic medical device company. Firefly will introduce NeuroSigma's Monarch eTNS System to the psychiatry, neurology and behavioral health practices that already use Firefly's FDA 510(k)-cleared, AI-powered Evoke EEG/ERP platform, expanding clinician awareness of and access to the device across Firefly's nationwide customer network.

How much did AIFF stock move on the news?

Firefly Neuroscience shares rose 34.45% to $1.60 as of the last trade at 16:04 GMT on Sept. 25, 2026, from a prior close of $1.19. The stock traded as low as $1.48 and as high as $1.77 during the session, a wide intraday range typical of low-priced small-cap listings reacting to a single announcement.

What is the Monarch eTNS System?

The Monarch eTNS System is a bioelectronic device made by NeuroSigma that delivers external trigeminal nerve stimulation. It is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder cleared by the U.S. Food and Drug Administration, offering clinicians and families an alternative pathway to stimulant medication for eligible patients.

What is Firefly's Evoke platform?

Evoke is Firefly Neuroscience's FDA 510(k)-cleared, AI-powered EEG/ERP platform. EEG records the brain's electrical activity; ERP captures the brain's response to specific stimuli. Together they give clinicians objective data on brain function to support assessment, which Firefly is now pairing with a non-medication treatment option through the NeuroSigma agreement.

How large is the pediatric ADHD population the deal targets?

A 2024 study published in the Journal of Clinical Child & Adolescent Psychology found that approximately one in nine U.S. children has received an ADHD diagnosis. That prevalence underpins the commercial rationale for pairing objective brain-function measurement with an FDA-cleared, non-drug treatment option in psychiatry and behavioral health practices.

Were financial terms of the partnership disclosed?

No. The announcement did not include a revenue share, upfront payment, milestone structure, exclusivity provision or target for device placements. Without those details, the agreement is a distribution arrangement of unquantified value, and the share price reaction reflects expected future business rather than revenue already contracted or booked.

Sources

• Firefly Hikes on Partnering with NeuroSigma — Baystreet